Definium Therapeutics, Inc. is trading 13.4% up at $27.75 in pre-market. The company is discussing topline results from its Phase 3 Emerge study in Major Depressive Disorder today, a key event for its late-stage CNS pipeline. This follows an announcement on June 21, 2026, regarding the webcast for the results. The price surge extends a multi-day uptrend, also supported by prior bullish analyst targets.